No Data
No Data
No Data
No Data
No Data
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050
USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of...
PR NewswireMay 1 22:05
Boundless Bio Initiated at Outperform by Leerink Partners
Boundless Bio Initiated at Outperform by Leerink Partners
Dow JonesApr 23 03:21
Boundless Bio (BOLD.US) was first covered by Leerink Partners, which gave it an superior market rating and a target price of $25.00.
Boundless Bio (BOLD.US) was first covered by Leerink Partners, which gave it an superior market rating and a target price of $25.00.
Zhitong FinanceApr 23 03:20
Leerink Partners Initiates Coverage On Boundless Bio With Outperform Rating, Announces Price Target of $25
Leerink Partners analyst Michael Cherny initiates coverage on Boundless Bio with a Outperform rating and announces Price Target of $25.
Analyst UpgradesApr 23 03:11
Boundless Bio Price Target Announced at $24.00/Share by Guggenheim
Boundless Bio Price Target Announced at $24.00/Share by Guggenheim
Dow JonesApr 22 19:28
Analysts' Opinions Are Mixed on These NA Stocks: Boundless Bio Inc. (BOLD) and Solventum Corporation (SOLV)
TipRanksApr 22 18:40
No Data
No Data